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Abstract: In a modern world, where day-to-day worry and stress prevails, along with an ever-increasing workday, 
care with diet is often overlooked and, combined with a sedentary lifestyle, increases obesity rates in all the world. 
The purpose of this work is to analyze society's view about the treatment of obesity with medications, comparing it 
with the treatment of other diseases, such as high blood pressure and diabetes. Through a questionnaire, on the 
internet, carried out from July to September 2020, with 14 multiple-choice questions answered by 520 people, 
91.7% of the participants answered that obesity is a disease, however, 47.3% of people still think that the use of 
drugs for their treatment is not necessary and only 37.7% believe in the effectiveness of such a method. In 
addition, 26.2% believe that all obese people eat a high amount of food and practice little physical activity. As for 
the comparison with other diseases, 33.3% of the respondents believe that diabetes should be treated with 
medication and obesity should not, and 32.3% believe that hypertension should use this method and obesity 
should not. With such results, it was concluded that the society's view is still quite stigmatized regarding the 
treatment of obesity by drugs, which implies prejudice and the difficulty in adhering to this method by obese 
people and, with this, is the difficulty in reducing the rates obesity and all comorbidities related to it. 
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1. Introduction 
 Obesity, by definition of the Obesity Medicine 
Association, is a chronic, relapsing, multifactorial 
neurobehavioral disease, in which an increase in body 
fat promotes dysfunction of adipose tissue and 
abnormal physical forces of fat mass, resulting in 
adverse metabolic, biomechanical, and psychosocial 
consequences to health [1,2]. It is noteworthy that 
obesity affects more than 20 million Brazilians. In the 
adult population, 12.5% of men and 16.9% of women 
are obese and about 50% are overweight. In the 
United States, 64.5% of the adult population is 
overweight [2,3]. 
 Thus, the American Medical Association (AMA) 
decided to classify obesity as a disease in 2013 to help 
the medical community to deal with this comorbidity 
[4,5]. Over the years, other entities, including the 
World Health Organization (WHO), have recognized 
the condition as a chronic disease, which needs 
specific and long-term treatment [6-8]. 
 Still, it is highlighted that obesity has its place 
in the International Disease Code (ICD), with E66-0 
Obesity due to excess calories, E66-1 Drug-induced 
obesity, E66-2 Extreme obesity with alveolar 
hypoventilation, E66- 8 Other Obesity and E66-9 
Obesity, unspecified [9]. This fact corroborates the 
AMA classification. 
 It is known that this comorbidity is 
multifactorial, not always being associated with 
excessive calorie consumption or lack of physical 
activities. There are also causes genetic factors, 
impaired metabolic pathways, disordered signaling of 
hunger and satiety, stress-induced obesity or 
menopause, dysregulation of the nutroneurometabolic 
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system [10]. Thus, it is noted that obesity is related to 
genetic, psychological, physical, metabolic, 
neurological, and hormonal factors, being complex 
pathogenesis [7]. 
 Thus, obesity is a multifactorial and chronic 
evolution syndrome, which requires chronic treatment 
5. The best form of treatment is with lifestyle changes, 
with fewer caloric diets combined with physical 
exercises, under the supervision of professionals. If 
only that is not effective, there must be a cognitive-
behavioral change. Still, it is worth mentioning the use 
of pharmacotherapy, accompanied by a nutrologist or 
endocrinologist, who is effective and very valid in the 
anti-obesity treatment, and for more severe cases, 
bariatric surgery is recommended [8]. 
 Treatment should reduce weight to the point 
that conditions associated with obesity, such as 
hyperglycemia, dyslipidemia, arterial hypertension, 
heart failure, sleep apnea, and others, are attenuated 
or absent [11]. 
 Drugs aimed at the treatment of obesity have 
several functions in the body and in helping weight 
loss. Some examples are Sibutramine, 
Catecholaminergic (diethylpropion, fenproporex, 
phentermine, and mazindol, are anorexigenic), Orlistat 
(decreases the absorption of triglycerides and 
encourages long-term adherence to food consumption 
with less fat content), Fluoxetine, and Sertraline (they 
are not efficient anti-obesity drugs, but they can be 
useful for the treatment of obese depressants as they 
reduce food intake), Thermogenic (such as caffeine, 
theophylline, aminophylline and aspirins cause the 
increased duration of noradrenaline activity), 
Topiramate (anticonvulsant with weight loss effects, 
prescribed for binge eating) [11]. 
 Therefore, the present study aimed to identify 
and analyze the population's view of the treatment of 
obesity by drugs. Through targeted questions, observe 
the stigma of pharmacotherapy for the treatment of 
obesity compared to other chronic diseases, such as 
hypertension and diabetes. 
 
2. Methods 
2.1 Study Design 
The present study followed an 
observational/epidemiological descriptive model on the 
view of Brazilian society on the use of medications for 
the treatment of obesity through 14 questions 
organized in a digital form on the Internet from July to 
September 2020, following the STROBE rules 
(Strengthening the Reporting of Observational Studies 
in Epidemiology - https://www.strobe-
statement.org/index.php?id=strobe-home) [12]. 
 
2.2 Approach Criteria 
The opinions of a random audience were 
analyzed, including medical students (27.6%), doctors 
(3.1%), and people working in other categories 
(69.4%), totaling 520 participants. The questions 
asked were personal opinions as to the motivations 
that lead to obesity, the classification of the condition 
as a disease or not, the use of medications as 
treatments and their implications, whether obese 
suffer or not prejudices, the influence of genetic 
factors and lifestyle styles. Overweight life, if there are 
only unique patterns with specific results regarding 
body aesthetics and the importance of the doctor in 
the treatment of obesity, in addition to issues 
comparing the treatment of obesity with that of 
hypertension and diabetes. 
 
3. Results 
From the questionnaire (composed of 14 
questions) answered by 520 participants, it was 
possible to access some results that are important for 
the conclusion and purpose of the work (Table 1). 
Therefore, it was observed that the majority of people 
who answered the questionnaire were not doctors 
(only 3.1% were doctors) or medical students 
(27.6%), but had other occupations (69.4%), 
according to Figure 1. 
Figure 1 Results of the types of participants in relation 
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As previously mentioned, 91.7% of the 
participants answered “yes” to the question that asked 
whether obesity is a disease, however, regarding the 
question of the need for medications to help treat 
obesity, the number was much lower (52.7 %) of the 
participants replied believing that these drugs are 
necessary, and of these, only 29.4% rated their 
importance as high. In addition, 36% of participants 
responded that they did not believe in the 
effectiveness of drugs in the treatment of obesity. 
These numbers show the misinformation of a 



















obesity a disease that is often neglected and 
treated incorrectly and ineffectively. One of the factors 
that corroborate this situation is the recent recognition 
of obesity as a disease. 
It is worth mentioning that only in 2013 did the 
American Medical Association (AMA) classify obesity as 
a disease in order to help the medical community to 
deal with this comorbidity. After that, some entities 
such as the World Health Organization (WHO), started 
to recognize the condition as a chronic disease, which 
needs long-term treatment [2]. Still, it should be noted 
that obesity has its place in the International Disease 
Table 1 Results of questions and answers - Questionnaire on the use of medications 
for the treatment of obesity at the Brazilian national level  
Is obesity a disease? 
Yes: 91.7% and No: 8.3%. 
Is there prejudice against obesity? 
Yes: 91.5%; No: 8.5% 
Is there a need for medications to aid treatment for obesity? 
Yes: 52.7%; No: 47.3% 
Does every obese person eat a large amount of food and practice little physical 
activity? 
Yes: 26.2% 
Does every excessively thin individual eat little and do a lot of physical activity? 
Yes: 4.4% 
Does obesity stem only from lifestyle and dietary patterns? 
No: 91% 
Is obesity influenced by genetic factors? 
Yes: 97.1% 
Is the use of medications effective? 
Yes: 62.3% 
As for effectiveness? 
41.5% in the long run 
22.5% in the short term 
36% do not believe in the effectiveness 
Should the purchase of medicines depend on medical prescription? 
Yes: 1.2% 
Should hypertension be treated with medication and obesity not? 
Yes: 32.3% 
Should diabetes be treated with medications and obesity not? 
Yes: 33.3% 
Is the use of drugs for the treatment of obesity important? 
No: 4.8% 
High importance: 29.4% 
Average importance: 48.3% 
Low importance: 17.5% 
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Code (ICD), with E66-0 obesity due to excess calories, 
E66-1 Drug-induced obesity, E66-2 extreme obesity 
with alveolar hypoventilation, E66 -8 other obesity, 
and E66-9 unspecified obesity [9]. 
Analyzing the ICD itself and the definitions of 
obesity, it is possible to contemplate another point 
addressed by the questionnaire used in the research, 
where 23% of the participants answered that they 
believe that every obese individual consumes a high 
amount of calories and practices little physical activity. 
However, this is only one of the 5 types of obesity 
specified in the ICD [9]. 
According to the International Obesity Task 
Force (IOTF), as well as the I and II Latin American 
Consensus on Obesity (1998 and 2002, respectively), 
pharmacological treatment is indicated when the 
patient has a body mass index (BMI) greater than 30 
kg / m², the patient has one or more diseases 
associated with overweight (comorbidities) with a BMI 
greater than 25 kg / m², treatment with diet, 
cognitive-behavioral changes, exercise and/or 
increased physical activity have already been proven 
tried, without success (FAO) [11]. 
 Since obesity is a chronic disease, so must its 
treatment, and its objective must be to reach a weight 
in which conditions associated with obesity, such as 
hyperglycemia, dyslipidemia, arterial hypertension, 
heart failure, sleep apnea, among others, are absent 
or attenuated. In view of this purpose, the opinion of 
experts and the medical literature is unanimous that 5 
to 10% of body weight loss is often sufficient [2,5]. 
 The most used criteria for assessing the 
effectiveness of anti-obesity treatments are those of 
the Food and Drug Administration (FDA) and the 
Committee of the European Agency for the Evaluation 
of Medicinal Products (CPMP). The FDA cites as a 
criterion a weight loss greater than 5% compared to 
placebo and that is statistically significant, while the 
CPMP suggests a loss greater than 10% compared to 
placebo [5]. 
 In this context, a systematic review study 
followed by a meta-analysis of randomized clinical 
trials in the last five years explored the efficacy and 
safety of anorexigenic drugs for weight reduction and 
consequent treatment of obesity, with the use of 
sibutramine, phentermine, fenproporex, mazindol, 
amfepramone, orlistat. It was observed that in the last 
five years of randomized studies there were no 
significant general complications, with only 5.7%. The 
average global weight loss was 6.18 (± 2.8) kg in the 
meantime of 12 months. The overall success rate 
among these drugs was 80.18%. Thus, the scientific 
findings of randomized studies on the use of 
anorexigenic drugs in the treatment of obesity have 
shown safety and efficacy in the past five years, with 
reasonable weight loss and without significant 
complications [6]. 
 
5. Conclusion  
 According to the questionnaire and the 
answers obtained, it was concluded that the view of 
Brazilian society regarding the treatment of obesity 
with drugs prevails as a stigma, due to the high 
number of people who consider it as a disease 
(91.7%) and the discrepant number of people who 
believe that the use of drugs is not necessary for 
treatment (47.3%). Furthermore, it is likely that the 
late classification of obesity as a disease by health 
organizations, such as the World Health Organization, 
the American Medical Association, and the Brazilian 
Ministry of Health, corroborate for people to think that 
the use of drugs in the treatment of obesity 
unnecessary. 
 Still, compared to other diseases, the 
stigmatization of drugs in the treatment of obesity in 
relation to other chronic diseases is clear. Bearing in 
mind that 33.3% of the research participants believe 
that diabetes should be treated with medication and 
obesity should not, and 32.3% believe that systemic 
arterial hypertension should be treated with medication 
and obesity should not. Finally, it is worth mentioning 
that the stigmatization of medications for obesity 
implies prejudice and the difficulty of adhering to this 
method by obese people, and thus, the difficulty in 
decreasing the rates of obesity and the comorbidities 
associated with it. 
 
References 
[1] E.A. Finkelstein, O.A. Khavjou, H. Thompson, 
J.G. Trogdon, L. Pan, B. Sherry, W. Dietz, 
Obesity and severe obesity forecasts through 
2030, American Journal of Preventive Medicine, 
42 (2012) 563–570. DOI | PubMed  
[2] OMS- Organização Mundial de Saúde. Disponível 
em: https://www.sbcbm.org.br/endoscopia-e-
obesidade/ Acesso em: 16 de abril de 2020. 
[3] Instituto Brasileiro de Geografia e Estatística 
(IBGE). Acessado em 15 de maio de 2020. 
Disponível em: http://www.ibge.gov.br. 
[4] A. Karamitri, R. Jockers, Melatonin in type 2 
diabetes mellitus and obesity, Nature Reviews 
MedNEXT J Med Health Sci 2(1) (2021) 19-23 
 Vol 2 Iss 1 Year 2021                           Fernando Zanatta Junior et al.,/2021           
 
Page 23 of 23 
Endocrinology, 15(2) (2019) 105-125. DOI | 
PubMed 
[5] M. Schetz, A. De Jong, A.M. Deane, W. Druml, P. 
Hemelaar , P. Pelosi, P. Pickkers, A. Reintam-
Blaser, J. Roberts, Y. Sakr, S. Jaber, Obesity in 
the critically ill: a narrative review, Intensive 
Care Medicine, 45(6) (2019) 757‐769. DOI | 
PubMed 
[6] A.V. Garcia Ramirez, D.R. Filho, I.J. Zotarelli 
Filho, Meta-analysis and Approach of the Real 
Impact of Anorexigenic Drugs in the Obesity in 
Humans: The Last Five Years of the Randomized 
Studies. Current Diabetes Reviews, 16(7) (2020) 
750-758. DOI | PubMed 
[7] Why is obesity a disease? Obesity Medicine 
Association, 2017. Disponível em: 
<https://obesitymedicine.org/2017/02/08/why-
is-obesity-a-disease/>. Acesso em: 01 de set. de 
2020. 
[8] Rosenbaum P. Obesity. Einstein, 2020. Available 
at: <https://www.einstein.br/doencas-
sintomas/obesidade>. Accessed on: September 
1st. 2020. 
[9] CID 10. Company, 2013. Disponível em: 
<https://www.cid10.com.br/buscadescr?query=
obesidade>. Acesso em: 01 de set. de 2020. 
[10] Study points out that obesity is wrongly 
condemned by society. Associação Brasileira de 
Nutrologia, 2009. Available at: 
<https://abran.org.br/2018/06/08/estudo-
aponta-que-a-obesidade-e-erronamente-
condenada-pela-sociedade/>. Accessed on: 
September 1st. 2020. 
[11] Ribas Filho D, SUEN VMM. Tratado de 
Nutrologia. 1. ed. p. 273-278. São Paulo: 
Manole, 2013. 
[12] E.V. Elm, D.G. Altman, M. Egger, S.J Pocock, 
P.C. Gøtzsche, J.P. Vandenbroucke, STROBE 
Initiative, The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) 
Statement: Guidelines for Reporting 
Observational Studies, Journal of Clinical 
Epidemiology, 61(4) (2008) 344-349. DOI | 















Data collection, analysis and preparation of initial draft 
(FZJ, HGR, JGLdCP, JPPD, MML, AVGR & DRF); 
Designing the study, data collection, analysis, 
preparation and finalising the manuscript (IJZF). 
   
Data sharing statement 
No additional data are available  
 
Ethics Approval  
Not Applicable    
 
Informed consent 
Informed written consent obtained from the participant 
 
Conflict of interest  
The authors declare no conflict of interest. 
 
About The License 
© The author(s) 2020. The text of this article is open 
access and licensed under a Creative Commons 
Attribution 4.0 International License 
 
